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Introduction
In a previous study conducted by our group we observed
an unusual prevalence of tittles of antinuclear (ANA) and
anti-DNA (aDNA) antibodies in children who were pre-
viously negative for both antibodies and who received any
biologic therapy due to a childhood rheumatic systemic
disease (CRSD). This observation has been reported in
adulthood previously, mainly in patients exposed to anti
tumoral necrosis factor (aTNF) therapy however its clini-
cal impact is not well established.
Objectives
Present study was conducted to determine if aTNF ther-
apy administered on patients with Juvenile idiopathic
arthritis (JIA) shows the same tendency and if the ratio
of change is comparable to patients not exposed to this
therapy.
Methods
Medical records of our cohort of patients from 1999 to
2009 who underwent 62 an aTNF therapy due to any
ILAR category of JIA were reviewed. Analytical tests were
collected in the moment of diagnosis, at the beginning of
the aTNF treatment, and at the 3rd and 6th month of
treatment. Only cases with complete analytical testing up
to a month after the designed date were analyzed. Com-
parisons were made with children diagnosed with the
same ILAR category of JIA of the same age (+/- 2 years
old) and sex. Non exposed and exposed subjects ratio was
1:1. aDNA positive change was considered when a nega-
tive cuantitative determination changed to a positive one
according to our reference lab ranges (Indirect
immunofluorecense method). ANA increase was defined
as a two fold increase in the titter. In order to establish
comparisons only subjects susceptible to experiment an
ANA titter increase of an aDNA positive change were
chosen.
Results
The followed up treatments were: 32 Etanercept (ETN), 15
Infliximab (IFM), 15 Adalimumab (ADM), Anti-DNA
profile evolution: 3/25 showed a titter increase (12.0%), all
of them were previously negative (2 with ETN and 1 with
IFM). Into the control group no patient developed a titter
increase (p non available). ANA profile evolution: 12/49
showed a titter increase (24.4%), 8 with ETN and 4
with IFM. Into the control group 5/49 patients (10.2%)
experiment a titter increase (p < 0.05). No patient who
underwent a change into its autoimmune profile was sec-
ondarily diagnosed with other CRSD during the period of
follow up. The need of switching the biologic therapy, rate
of severe complications or demands of increase of non
biologic therapy was similar in children who increase its
ANA titters and who did not.
Conclusion
Our findings supports the hypothesis that aTNF therapy
plays a role into the change of the autoimmunity profile in
children with JIA. The most important fact around this
findings is related to the clinical repercussion. Although
we could not demonstrate any significant clinical impact it
is possible that longer periods of observation in larger ser-
ies can, so the close observation of the autoimmunity
profile should be, in the meantime, part of the follow up
of children with JIA exposed to aTNF therapy.
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